Reliance Life Sciences, which is controlled by Mukesh Ambani and is part of the country's largest conglomerate, is set to begin phase I clinical trials of its indigenous coronavirus vaccine soon.Reliance's recombinant Covid vaccine candidate has been recommended for Phase 1 clinical trials by the Subject Expert Committee (SEC). Reliance Life Sciences has previously applied for permission to conduct a Phase I trial of its planned two-dose coronavirus vaccine.
The Covid vaccine is being developed at the company's Navi Mumbai laboratory and would be "competitively priced," according to the company. During the SEC meeting on Friday, the business gained approval.Following the SEC's recommendations, Reliance Life Sciences must obtain approval from the Drug Controller General of India (DCGI) before beginning Phase 1 trials of the COVID-19 vaccine.
The trials will take place in 10 locations across India, including Tamil Nadu, Andhra Pradesh, Maharashtra, and Delhi. The first phase of the trial normally lasts 58 days in order to determine the maximum dose that most patients can take.Serum Institute of India's Covishield, Bharat Biotech's Covaxin, Zydus Cadila's vaccine, Russia's Sputnik V, Moderna, and Johnson & Johnson are among the six Covid-19 vaccines that have gained Emergency Use Authorization (EUA) in India thus far.
Shah Rukh Khan's son Aryan Khan was arrested on October 3 along with seven others aboard a cruise ship in Mumbai. The agency raided the ship and d...
Delhi Metro Rail Corporation (DMRC) will soon deploy an improved contactless ticketing system as part of a new system called Near Field Communication...